According to Greg Brockman (@gdb), OpenAI's GPT-5 is being applied in immunology, signaling a significant advancement in the use of large language models for biomedical research and clinical diagnostics (source: Greg Brockman on Twitter). The new version of GPT-5 is reported to enhance data analysis, accelerate literature review, and support hypothesis generation in immunological studies. This development opens business opportunities for biotech companies to integrate AI-powered solutions in drug discovery, personalized medicine, and disease prediction, making AI an essential tool in the competitive life sciences sector.

According to Greg Brockman (@gdb), ChatGPT has been applied to address a longstanding medical problem, showcasing its potential in clinical problem-solving and healthcare innovation (source: https://twitter.com/gdb/status/1941567568155902397). This development highlights the growing use of generative AI for medical diagnostics and research, providing opportunities for healthcare organizations to accelerate complex case analysis, improve diagnostic accuracy, and reduce time-to-treatment. With ChatGPT's integration in medical workflows, businesses in digital health and AI-driven healthcare services can capitalize on the trend of AI-powered clinical decision support, paving the way for enhanced patient outcomes and operational efficiency.